Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BM32 Skin Testing in Grass Pollen Allergy
NCT01350635Phase 2Completed
- Sponsor
- Biomay AG
- Start
- May 2011
- Primary completion
- Jul 2011
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of BM32 in allergic rhinitis due to grass pollen, sponsored by Biomay AG. Primary endpoint: Wheal size of immediate type skin reactions at 20 minutes. Started May 2011; status: completed.
02
Drugs
BM32
03
Conditions
allergic rhinitis due to grass pollen
Beyond the preview
Go deeper on NCT01350635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01350635.